Use App
New
Connect your Agent
Trending
News
Earnings
All
DIA
0.32%
SPY
0.03%
QQQ
0.17%
Trending
NFLX
3.60%
BA
0.03%
ONON
5.71%
SMCI
0.47%
BRUN
2.70%
ABEO
4.11%
WFC
0.62%
NCLH
0.14%
BRK.B
0.31%
NEAR
23.61%
Feed
News
Sentiment
Earnings
Fundamentals
Info
home
Symbol
LQDA
news
Exchange:
NASDAQ
·
Updated 08:03 AM EDT
LQDA News
News
all
press releases
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
Zacks
Share to Feed
More News
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
Zacks
Liquidia Corporation's (LQDA) Yutrepia Launch Continues to Outpace the Expectations
Liquidia Corporation's (LQDA) Yutrepia Launch Continues to Outpace the Expectations...
Yahoo! Finance: News
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Zacks
Is the Options Market Predicting a Spike in Liquidia Stock?
Investors need to pay close attention to LQDA stock based on the movements in the options market lately.
Zacks
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Zacks
Will LQDA's Differentiated PAH Approach Drive Growth?
LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.
Zacks
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
Zacks
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.
Zacks
Greenhaven Road Capital: Short Term Gain Realized from Liquidia (LQDA), Investment to Be Revisited
Greenhaven Road Capital: Short Term Gain Realized from Liquidia (LQDA), Investment to Be Revisited...
Yahoo! Finance: News
1
2
Advertisement
|
Remove ads.
Home
Watchlist
Trending
News
Explore
Profile